Upstream Bio Valuation
| UPB Stock | 30.02 1.77 5.57% |
At this time, the company appears to be undervalued. Upstream Bio has a current Real Value of USD34.66 per share. The regular price of the company is USD30.02. Our model measures the value of Upstream Bio from inspecting the company fundamentals such as Return On Equity of -0.41, shares owned by insiders of 14.77 %, and Current Valuation of 1.25 B as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Upstream Bio's valuation include:
Undervalued
Today
Please note that Upstream Bio's price fluctuation is not too volatile at this time. Calculation of the real value of Upstream Bio is based on 3 months time horizon. Increasing Upstream Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Upstream Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Upstream Stock. However, Upstream Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 30.02 | Real 34.66 | Target 49.75 | Hype 29.76 | Naive 30.12 |
The real value of Upstream Stock, also known as its intrinsic value, is the underlying worth of Upstream Bio Company, which is reflected in its stock price. It is based on Upstream Bio's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Upstream Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Upstream Bio helps investors to forecast how Upstream stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Upstream Bio more accurately as focusing exclusively on Upstream Bio's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Upstream Bio's intrinsic value based on its ongoing forecasts of Upstream Bio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Upstream Bio's closest peers. If more than one evaluation category is relevant for Upstream Bio we suggest using both methods to arrive at a better estimate.
Upstream Bio Cash |
|
Upstream Bio Total Value Analysis
Upstream Bio is at this time projected to have company total value of 1.25 B with market capitalization of 1.26 B, debt of 1.83 M, and cash on hands of . Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Upstream Bio fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.25 B | 1.26 B | 1.83 M |
Upstream Bio Investor Information
About 15.0% of the company outstanding shares are owned by insiders. The book value of Upstream Bio was at this time reported as 7.01. The company recorded a loss per share of 6.4. Upstream Bio had not issued any dividends in recent years. Based on the analysis of Upstream Bio's profitability, liquidity, and operating efficiency, Upstream Bio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.Upstream Bio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Upstream Bio has an asset utilization ratio of 0.49 percent. This suggests that the Company is making USD0.00492 for each dollar of assets. An increasing asset utilization means that Upstream Bio is more efficient with each dollar of assets it utilizes for everyday operations.Upstream Bio Profitability Analysis
Considering Upstream Bio's profitability and operating efficiency indicators, Upstream Bio may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in February. Profitability indicators assess Upstream Bio's ability to earn profits and add value for shareholders.Net Loss | First Reported 2010-12-31 | Previous Quarter -56.5 M | Current Value -59.4 M | Quarterly Volatility 14.2 M |
For Upstream Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Upstream Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Upstream Bio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Upstream Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Upstream Bio over time as well as its relative position and ranking within its peers.
Upstream Bio Earnings per Share Projection vs Actual
The next projected EPS of Upstream Bio is estimated to be -0.7 with future projections ranging from a low of -0.7425 to a high of -0.629275. Upstream Bio's most recent 12-month trailing earnings per share (EPS TTM) is at -6.4. Please be aware that the consensus of earnings estimates for Upstream Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.Upstream Bio Earnings Estimation Breakdown
The calculation of Upstream Bio's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Upstream Bio is estimated to be -0.7 with the future projection ranging from a low of -0.7425 to a high of -0.629275. Please be aware that this consensus of annual earnings estimates for Upstream Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.74 Lowest | Expected EPS | -0.63 Highest |
Upstream Bio Earnings Projection Consensus
Suppose the current estimates of Upstream Bio's value are higher than the current market price of the Upstream Bio stock. In this case, investors may conclude that Upstream Bio is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Upstream Bio's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 8 | 77.78% | -0.63 | -0.7 | -6.4 |
Upstream Bio Ownership Allocation
Upstream Bio shows a total of 54.04 Million outstanding shares. The majority of Upstream Bio outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Upstream Bio to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Upstream Bio. Please pay attention to any change in the institutional holdings of Upstream Bio as this could imply that something significant has changed or is about to change at the company. Also note that roughly four million three hundred sixty thousand nine hundred fourteen invesors are currently shorting Upstream Bio expressing very little confidence in its future performance.Upstream Bio Profitability Analysis
The company reported the last year's revenue of 2.37 M. Reported Net Loss for the year was (62.81 M) with profit before taxes, overhead, and interest of 2.8 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Upstream Bio's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Upstream Bio and how it compares across the competition.
About Upstream Bio Valuation
The stock valuation mechanism determines Upstream Bio's current worth on a weekly basis. Our valuation model uses a comparative analysis of Upstream Bio. We calculate exposure to Upstream Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Upstream Bio's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.7 M | 2.2 M | |
| Pretax Profit Margin | (30.48) | (32.00) | |
| Operating Profit Margin | (37.73) | (39.62) | |
| Net Loss | (30.48) | (32.00) |
Upstream Bio Current Valuation Indicators
Valuation refers to the process of determining the present value of Upstream Bio and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Upstream we look at many different elements of the entity such as Upstream's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Upstream Bio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Upstream Bio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Upstream Bio's worth.Complementary Tools for Upstream Stock analysis
When running Upstream Bio's price analysis, check to measure Upstream Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Upstream Bio is operating at the current time. Most of Upstream Bio's value examination focuses on studying past and present price action to predict the probability of Upstream Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Upstream Bio's price. Additionally, you may evaluate how the addition of Upstream Bio to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |